Ozempic and Wegovy – two brand-name semaglutide drugs prescribed for diabetes and weight loss – will lose market exclusivity ...

Intel's 2026 turnaround relies on AI trends, foundry growth, and competitive products. Learn what's at stake and what this ...

The S&P 500 was expected to end this year at 6,500 points, according to the consensus forecast in Reuters’ 2024 year-end poll. That implied a rise of around 9%. The index is on track to gain twice as ...

Discover top sector-focused investment strategies for 2026, with insights on AI, ETFs, and S&P 500 performance.